Ramachandran, Rajeswari and Balasubramanian, Rani and Santha Devi, T (1992) Short-course chemotherapy in neuro-tuberculosis - Brief review of clinical trials undertaken at the Tuberculosis Research Centre, Madras. Progress in Clinical Neurosciences. pp. 869-881.
![[thumbnail of 199214.pdf]](http://eprints.nirt.res.in/style/images/fileicons/application_pdf.png) Preview |
PDF
199214.pdf - Published Version Download (100kB) |
Abstract
Tuberculosis of the nervous system can present as tuberculous meningitis, tuberculoma of brain, Potts paraplegia, tuberculosis of spine and rarely as arachnoiditis and vasculitis. Tuberculosis is conventionally treated for 12 to 18 months to ensure adequate cure, stabilise quiescence and prevent relapses. With the introduction of rifampicin and pyrazinamide it became feasible to shorten the duration of chemotherapy to 6 to 9 months. Many controlled clinical trials conducted all over the world have confirmed the success of this approach in pulmonary tuberculosis by evolving 100% effective SCC regimens 1-5. In a few studies especially tuberculous lymphadenitis, tuberculous abdomen and pericarditis SCC has also been used and found to be as effective as conventional regimens6,7. However, only recently has SCC been tried for neurotuberculosis. This presentation briefly highlights some of the chemotherapy trials conducted at the Tuberculosis Research Centre in some areas of CNS tuberculosis8-10. What is SCC? SCC refers to chemotherapeutic regimens containing powerful bactericidal drugs like INH, Rifampicin and Pyrazinamide, by the use of which the duration of treatment of TB is reduced from the conventional 12 to 18 months to 6 to 9 months.
| Item Type: | Article |
|---|---|
| Subjects: | Tuberculosis > Clinical Research |
| Divisions: | Clinical Research |
| Depositing User: | Dr. Rathinasabapati R |
| Date Deposited: | 11 Sep 2013 10:56 |
| Last Modified: | 14 Mar 2016 07:27 |
| URI: | http://eprints.nirt.res.in/id/eprint/325 |
Actions (login required)
 |
View Item |